I-Mab ADR (IMAB)

$1.81 0.01 (0.56%)

16:00 EDT IMAB Stock Quote Delayed 30 Minutes

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

By William White, InvestorPlace Writer Sep 28, 2023

We're checking out the biggest pre-market stock movers worth watching on Friday with a dive into all of the latest market stories!

Why Is TRACON Pharma (TCON) Stock Down 51% Today?

HFCAA News: 128 Chinese Stocks the SEC Could Delist

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

Volume:

Previous Close -

Market Cap 345.49M

PE Ratio -0.94

EPS -1.92

Volume (Avg. Vol.) 109,542

Day's Range $1.80 - $1.82

52-Week Range $1.17 - $3.44

Dividend & Yield N/A (N/A)

IMAB Stock Predictions, Articles, and I-Mab ADR News

From InvestorPlace
From the Web

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

By William White, InvestorPlace Writer Dec 15, 2021

We're at the halfway point of the week but there's no slowing down as we dive into the biggest pre-market stock movers for Wednesday!

7 of the Best Pharma Stocks to Buy Now

By Louis Navellier and the InvestorPlace Research Staff May 11, 2021

As the market gets back to normal, it's a great time to explore the pharma stocks that got lost in the vaccine frenzy of the past year.

Biopharma News: IMAB Stock Soars 4% on AbbVie Pact

By William White, InvestorPlace Writer Sep 4, 2020

I-Mab (IMAB) is seeing gains to IMAB stock on Friday after the biopharma company announced news of a deal with AbbVie (ABBV).

I-Mab stock dips on plans to divest Chinese assets

From Seeking Alpha Feb 7, 2024

I-Mab (IMAB) plans to divest its assets and business operations in China as it aims to become a US-based biotech amid rising geopolitical concerns. Read more here.

I-Mab gains FDA breakthrough tag for kidney disease therapy

From Seeking Alpha Nov 2, 2023

I-Mab (IMAB) wins FDA breakthrough therapy status for its CD38-targeting monoclonal antibody felzartamab to treat primary membranous nephropathy. Read more here.

Tracon stock falls after I-Mab gets favorable ruling in arbitration

From Seeking Alpha Apr 25, 2023

I-Mab (IMAB) said an arbitration tribunal awarded no damages to Tracon Pharmaceuticals (TCON) related to a collaboration agreement. Read more here

MGNX stock cut to Neutral at Citi, Guggenheim upgrades (NASDAQ:MGNX)

From Seeking Alpha Nov 23, 2022

MacroGenics (MGNX) has garnered attention on Wall Street this week, with Citi downgrading the commercial-stage biotech on Wednesday to Neutral from Buy after an upgrade from Guggenheim...

Needham Remains a Buy on I-MAB (IMAB)

From TipRanks Sep 12, 2022

Needham analyst Gil Blum maintained a Buy rating on I-MAB (IMAB – Research Report) today and set a price target of $33.00. The company’s shares opened t...

H.C. Wainwright Remains a Buy on I-MAB (IMAB)

From TipRanks Sep 12, 2022

In a report released today, Andrew Fein from H.C. Wainwright maintained a Buy rating on I-MAB (IMAB – Research Report), with a price target of $45.00. The com...

I-Mab ADR (IMAB)

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

Why Is TRACON Pharma (TCON) Stock Down 51% Today?

HFCAA News: 128 Chinese Stocks the SEC Could Delist

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

Top 5 Stocks for 2024

Louis Navellier's Total Grade

Is ? a BUY?

Louis Navellier's Total Grade

Louis Navellier's Total Grade

Fundamental Grade

Quantitative Grade

I-Mab ADR (IMAB)

Top 5 Stocks for 2024

Louis Navellier's Total Grade

Is ? a BUY?

Louis Navellier's Total Grade

Louis Navellier's Total Grade

Fundamental Grade

Quantitative Grade

IMAB Stock Predictions, Articles, and I-Mab ADR News

Subscriber Sign in